bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2510
-0.0109 (-4.16%)
Mar 31, 2025, 1:13 PM EDT - Market open
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $2.35M in the quarter ending September 30, 2024, with 687.44% growth. This brings the company's revenue in the last twelve months to $9.37M, up 2,813.87% year-over-year. In the year 2023, bioAffinity Technologies had annual revenue of $2.53M with 52,627.44% growth.
Revenue (ttm)
$9.37M
Revenue Growth
+2,813.87%
P/S Ratio
0.30
Revenue / Employee
$124,904
Employees
75
Market Cap
3.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBIAF News
- 3 hours ago - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Business Wire
- 5 days ago - Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - Business Wire
- 12 days ago - Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - Business Wire
- 18 days ago - Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer - Business Wire
- 25 days ago - bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth - Business Wire
- 4 weeks ago - WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million - PRNewsWire
- 4 weeks ago - bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million - Business Wire
- 4 weeks ago - WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million - PRNewsWire